BioCryst Sells European ORLADEYO Business for $250M Upfront to Focus on US Market

BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) is one of the best stocks to buy under $20. On October 1, BioCryst Pharmaceuticals announced the successful completion of the previously announced sale of its European ORLADEYO (berotralstat) business to Neopharmed Gentili. The transaction is valued at $250 million upfront, subject to customary purchase price adjustments, with the potential for BioCryst to receive up to $14 million in future milestones based on sales in Central and Eastern Europe.

The divestiture immediately improves BioCryst’s operating margin, as the European business was ~breakeven on a direct basis. BioCryst will now focus on driving ORLADEYO sales in the US, while Neopharmed Gentili will lead commercialization across Europe, retaining the European commercial organization built by BioCryst for operational continuity.

Despite the exclusion of European revenue after the close, BioCryst remains on track to meet the upper half of its 2025 revenue guidance range of $580 million to $600 million.

BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) is a biotechnology company that develops oral small-molecule and injectable protein therapeutics to treat rare diseases.

While we acknowledge the potential of BCRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.